Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
Chien-Shing Chen, MD, PhD
Head, Medicine, Hematology/Oncology Division
School of Medicine
Professor, Medicine
School of Medicine
Professor, Basic Sciences
School of Medicine
Publications    Scholarly Journals--Submitted
  • Tan J, Yang X, Jiang X, Zhou J, Li Z, Lee PL, Aau M, Luo W, Liu SC, Wang J, Ong CT, Hooi SC, Chen CS, Li B, Wei CL5, Liu ET, Robson P, Ruan Y, and Yu Q. Epigenome analysis identifies differentiation regulator HAND1 as a tumor suppressor in colon cancer and is inactivated by both DNA and histone methylations.   Journal of Clinical Investigation, Submitted. ( 9/2009 - 9/2010 )
  Scholarly Journals--Published
  • Rodriguez JP, Murphy MP, Hong S, Madrigal M, March KL, Minev B, Harman RJ, Chen CS, Timmons RB, Marleau AM and Riordan NH.   Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. International Archives of Medicine 2012, 5:5   doi:10.1186/1755-7682-5-5

    ( 4/2012 )
  • Zhou J, Bi C, Chng W-J*, Cheong LL, Liu S-C, Mahara S, Tay K-G, Zeng Q, Li J, Guo K, Tan CPB, Yu H, Albert D, Chen CS*.  PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.  PLoS ONE 2011, 6(5): e19798. doi:10.1371/journal.pone.0019798. [*: Corresponding authors] (I.F. 4.411) (Evaluated by Faculty of 1000 and received FFa 8, Must Read)

    ( 4/2012 )
  • Berenson JR, Yellin O, Kazamel T, Hilger JD,  Chen CS, Cartmell A,  Woliver T, Flam M, Bravin E, Nassir Y,  Vescio R, Swift RA.  A Phase 2 Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone, and Lenalidomide for Patients with Relapsed/Refractory Multiple Myeloma.  Accepted for publication in Leukemia, 2012.

    ( 4/2012 )
  • Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, Yu Q, Chen CS, Chng WJ. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS ONE 2011, 6(6):e21583. (I.F. 4.411)

    ( 4/2012 )
  • Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, Moore PK, Deng LW. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS ONE 2011, 6(6): e21077.

    ( 4/2012 )
  • Xiong L, Darwanto A, Sharma S, Herring J, Hu S, Filippova M, Filippov V, Wang Y, Chen CS, Duerksen-Hughes PJ, Sowers LC and Zhang K. Mass spectrometric studies on epigenetic interaction networks in cell differentiation. Journal of Biological Chemistry.  First Published on February 18, 2011, doi: 10.1074/jbc.M110.204800.

    ( 4/2012 )
  • Ichim TE, Minev B, Braciak T, Luna B, Hunninghake R, Mikirova NA, Jackson JA, Gonzalez MJ, Massari JRM, Alexandrescu DT, Dasanu C, Bogin V, Ancans J, Stevens RB, Markosian B, Koropatnick J, Chen CS and Riordan NH. Intravenous Ascorbic Acid to Prevent and Treat Cancer-Associated Sepsis? Journal of Translational Medicine, 9:25, 2011.


    ( 4/2012 )
  • Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, and Lilly M.  Combination therapy of recurrent prostate cancer with the proteasome inhibitor Bortezomib plus hormone blockade.  Cancer Biology and Therapy. July 15; 12(2), 2011. [Epub ahead of print].


    ( 4/2012 )
  • Raja M. A., Xu S., Tai D.C.S , Sun W., Zhou J., Chen C.S., Rajapakse J.C., So P.T.C., Yu H. Pulse Modulated Second Harmonic Imaging Microscope (PM-SHIM) imaging quantitatively demonstrates marked increase of collagen in tumor after chemotherapy. J Biomed Opt. 2010 Sep-Oct;15(5):056016. (I.F. 2.87)


    ( 4/2012 )
  • Xie Z, Chng WJ, Tay KG, Liu SC,  Zhou J , Chen CS*.Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers.  Biotechnology Letters, 33:221–228, 2011. [*: Corresponding author]


    ( 4/2012 )
  • Tai Dean CS, Tan N, Xu S, Kang CH, Chia SM, Cheng CL, Wee A, Wei CL, Mythreyi Raja A, Xiao G, Chang S, Rajapakse JC, So Peter TC , Tang HH, Chen CS, Yu H. “Fibro-C-Index: comprehensive, morphology-based quantification of liver fibrosis using second harmonic generation and two-photon microscopy” Journal of Biomedical Optics Vol. 14, 044013, 1-10, Jul 27, 2009.


    ( 4/2012 )
  • Bautista M, Stevens WT, Chen CS, Curtis B, Aster R, Hsueh CT. Hypersensitivity Reaction and Acute Immune-mediated Thrombocytopenia from Oxaliplatin: Report of Two Cases and Review of Literature. Journal of Hematology & Oncology 3:12, 2010. http://www.jhoonline.org/content/3/1/12

    ( 3/2010 - 3/2012 )
  • Zhou J, Bi C, Janakakumara JV, Liu S-C, Tay K-G, Poon L-F, Xie Z, Palaniyandi S, Yu H, Wee-Joo Chng W-J, Glaser K, Albert D, Davidsen S, Chen CS.  Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.  Blood, 113:4052-4062, 2009. [*: Corresponding author] [Paper highlighted on the cover and Blood editorial: Briesewitz R. Fathoming Flt3. 2009 113: 3889-3890] (I.F. 10.558)

    ( 1/2009 - 12/2010 )
  •  Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, and Goh BC. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. Journal of Clinical Oncology 2009 Aug 31, 2009:doi:10.1200/JCO.2008.21.7125.


    ( 1/2009 - 12/2010 )
  • Zhou J, Goh BC, Albert D, Chen CS. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. Journal of Hematology & Oncology 2009, 2:33 doi:10.1186/1756-8722-2-33


    ( 9/2009 - 9/2010 )
  • Li Ching Lee, Chien-Shing Chen, Pei Feng Choong, Adrian Fatt-Hoe Low, Huay Cheem Tan, Kian Keong Poh.  Time-dependent Dynamic Mobilization of Circulating Progenitor Cells during Percutaneous Coronary Intervention in Diabetics.  International Journal of Cardiology 2009, doi:10.1016/j.ijcard. 2008.11.198.


    ( 1/2009 - 1/2010 )
  • Zhou J, Pan M, Loh S, Xie Z, Lim Y, Lilly MB, Han JH, Glaser K, Albert D, Davidsen S, Chen CS.  Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle regulated genes and c-Mos-mediated MAPK pathway.  Leukemia  2008;22:138-46. Epub 2007 Oct 18 ( 1/2008 - 12/2009 )
  • Xie Z, Choong PF, Poon L-F, Zhou J, Khng J, Janakakumara, JV, Palaniyandi S, Chen CS.  Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion”  Cancer Chemotherapy and Pharmacology. 2008 Feb 8; [Epub ahead of print]

    ( 1/2008 - 1/2009 )
  • Zhou J, Janakakumara, JV, Bi C, Neo S, Pan M, Poon L-F, Xie Z, Yu H, Yeoh E-J, Lu Y, Glaser K, Albert D, Davidsen S, Chen CS.  In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor, Leuk Res. 32:1091–1100, 2008. ( 1/2008 - 1/2009 )
  • Janakakumara, JV, Xie Z, Zhou J, Khng J, Poon L-F, Palaniyandi S, Glaser KB, Albert DH, Davidsen SK, and Chen CS.  ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. Journal of Hepatology, Dec;49(6):985-97.2008. [*: Corresponding authors]

    ( 1/2008 - 12/2008 )
  • Koh LP, Chen CS, Tai B-C, Hwang WYK, Tan LK, Ng HY, Linn YC, Koh MBC, Goh YT, Liu TC, Mow MF, Tan B, Ng HJ, Loh SM, Tan KW, Chuah TH, Tan CL, Tan HC.  Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Haematopoietic Stem Cell Transplant Using the Fludarabine and Low Dose Total Body Irradiation 2 Gy.  Biol Blood Marrow Transplant  13:790-805, 2007.


    ( 9/2007 - 9/2008 )
  • NG, Angela PP, Nin DS, Fong JH, Venkataraman D, Chen CS, and Khan M. Therapeutic targeting of nuclear receptor co-repressor (N-CoR) mis-folding in acute promyelocytic leukemia (APL) cells with genistein.  Molecular Cancer Therapeutic, Aug;6(8):2240-8, 2007. ( 1/2007 - 1/2008 )
  • Choong L-Y, Lim S, Marie Loh C-S, Xiaohui M, Chen Y, Toy W, Pan M, Chen, CS, Poonepalli A, Hande PM, Tan P-H, Salto-Tellez M, Wong C-Y, Shah N, Druker BJ and Lim YP.  Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Mol Cancer Ther. 2007 Nov; 6(11):2828-42. Epub 2007 Nov 7. ( 1/2007 - 1/2008 )
  • Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin D, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes MD, McDonagh KT, McLaughlin B, Molitor JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener M, Seibold JR, Sullivan KM, Furst DE. High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Systemic Sclerosis: U.S. Multi-center Pilot Study.  Blood 15;110(4):1388-96, 2007. ( 1/2007 - 1/2008 )
  • Shen J, Tai YC, Zhou J, Wong CHS, Cheang PTS, Wong WSF, Khan M, Han JH, Chen CS. Synergistic anti-leukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling.  Exp Hematology, (35)1: 75-83, 2007.

    ( 1/2007 - 12/2007 )
  • Zhang DH, Tai YC, Wong CHS, Koay SC, Chen CS.  Deciphering the molecular response of leukemia HL-60 cells to genistein treatment by proteomics approach. Leukemia Research, 31(1): 75-82, 2007.

    ( 1/2007 - 12/2007 )
  • Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB.  Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochemical Pharmacology, 72(10),1257-1267, 2006. ( 1/2006 - 1/2007 )
  • NG, Angela PP, Howe FJ, Dawn NS, Hirpara JL, Asou N,  Chen CS, Pervaiz S and Khan M. Cleavage of Mis-folded N-CoR in APL Cell by a Glycoprotein Endopeptidase Confers Resistance to UPR-induced Apoptosis. Cancer Research, 66(20): 9903-12, 2006. ( 1/2006 - 12/2006 )
  • Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M, Lane SR. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.  Ann Oncol. Jan;16(1):97-101, 2005. ( 1/2005 - 1/2006 )
  • Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, DiPersio J, LeMaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA.  Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder After High-Dose Immunosuppressive Therapy And Autologous CD34-Selected Hematopoietic Stem Cell Transplantation For Severe Autoimmune Diseases. Biol Blood Marrow Transplant, 9:583-91, 2003. ( 1/2003 - 1/2004 )
  • Chen CS, Seidel K, Boeckh M, Clark J, Madtes D, Wagner J, witherspoon R, Anasetti C, Appelbaum FR, Bensinger W, Deeg HJ, Sanders JE, Storb R, Wade J, Siadak M, Flowers MED and Sullivan KM.  Incidence and risk factors for developing pneumonia late after autologous and allogeneic hematopoietic stem cell transplantation. Blood Marrow Transplant  32, 515-522, 2003. ( 1/2003 - 1/2004 )
  • McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE.  High-dose Immunosuppressive Therapy for Severe Systemic Sclerosis - Initial Outcomes. Blood  1;100(5):1602-10, 2002. ( 1/2002 - 1/2004 )
  • Sweetser DA, Chen CS, Flowers DA, Galipeau PC, Barrett MT, Heerema NA, Bernstein ID, and Reid BJ. Loss of heterozygosity (LOH) in childhood de novo acute myelogenous leukemia. Blood98:1188-1194, 2001. ( 1/2001 - 1/2003 )
  • Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM,     Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, and Sullivan KM.  “ Safeguarding the administration of high-dose chemotherapy: A national practice survey by the American Society for Blood and Marrow Transplantation.” Biol. Blood Marrow Transplant. 3:331-340, 1997. ( 1/1997 - 1/1999 )
  • Chen CS, Bejcek BE, Kersey JH. “A Mapping study of 13 genes on human chromosome bands 4q11-q25.” Cytogenet. cell Genet. 69:260-265, 1995. ( 1/1995 - 1/1996 )
  • Sorensen PHB, Chen CS, Smith, FO, Arthur DC, Domer PH, Bernstein ID, Korsmeyer SJ,  Hammond GD, Kersey JH. “ Molecular rearrangements of the MLL gene are present in most cases of infant Acute Myeloid Leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes.” J. Clin. Invest. 93:429-437, 1994. ( 1/1994 - 1/1996 )
  • Chen CS, Hilden JM, Frestedt J, Domer P, Moore R, Korsmeyer SJ, Kersey JH. “ The chromosome 4q21 gene (AF-4/FEL) is widely expressed in normal tissues and shows breakpoint diversity in t(4;11)(q21;q23) acute leukemia.” Blood 82:1080-1085, 1993. ( 1/1993 - 1/1995 )
  • Domer PH, Fakharzadeh SS, Chen CS, Jockel J, Johansen L, Silverman GA, Kersey JH, Korsmeyer SJ. “The acute mixed lineage leukemia associated t(4;11)(q21;q23) produces an MLL-AF-4 fusion transcript.” Proc NatlAcadSci USA 90:7884-7888, 1993. ( 1/1993 - 1/1995 )
  • Chen CS, Sorensen PHB, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA, Hammond GD, Kersey JH. “ Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome.” Blood 81:2386-2393, 1993. ( 1/1993 - 1/1995 )
  • Hilden JM, Chen CS, Moore R, Frestedt J, Kersey JH. “ Heterogeneity in MLL/AF-4 fusion messenger RNA detected by the polymerase chain reaction in t(4;11) acute leukemia.” Cancer Research 53: 3853-6, 1993. ( 1/1993 - 1/1994 )
  • Chen CS, Medberry PS, Arthur DC, and Kersey JH. “ Breakpoint clustering in t(4;11)(q21;q23) acute leukemia.”  Blood 78:2498-2504, 1991. ( 1/1991 - 1/1993 )